When given at low-dosage over three months (which is more consistent with administration in a preventive setting), no sensitising effect was observed in three lung cancer cell lines exhibiting different mutational spectra (A549: K-ras mutant; PC9: EGFR driver mutation; PC9ER: EGFR driver mutation but exhibiting erlotinib resistance). The gene discussed is KRAS; the disease is lung carcinoma.